About Advaccine | Advaccine

Who We Are

Advaccine is an innovative vaccine company with a high-value prophylactic and therapeutic vaccine pipeline driven by in-house developed technology platforms.

Driven by innovative science and our research and development efforts our competitive pipeline consists of potential first-in-class key assets developed to address diseases caused by SARS-CoV-2, RSV and HBV, which are diseases with huge unmet medical needs. We are also developing vaccine candidates in preclinical stage covering oncology, as well as neoantigen therapeutic vaccines and tumor-associated antigen therapeutic vaccines. To deliver our transformed vaccines to society, we have embedded the commitment in all aspect of our work.

Our Team

Milestone

Oct 2016

Feb 2017

Mar 2017

Jul 2018

Nov 2019

Jan 2020

Feb 2020

Jun 2020

Jul 2020

Sep 2020

Nov 2020

Dec 2020

Mar 2021

Completed the pilot test for ADV110.

Suzhou Advaccine, our principal operating subsidiary, established.

Completed Round I Investment and raised approximately RMB20 million.

Initiated the Phase I clinical trial of ADV110 in Australia.

We successfully completed the Phase I clinical trial of ADV110.

Advaccine entered into a memorandum of understanding with INOVIO relating to the initiation of co-development of pGX9501 (INO4800) against COVID-19.

We completed the Round II Investment and raised approximately RMB40 million.

Completed the Round III Investment and raised approximately RMB 42 million.

We obtained the umbrella approval for initiation of Phase I/II clinical trials of pGX9501 from the NMPA.

Initiated the Phase I clinical trial of pGX9501 and also received the approval for the commencement of Phase II clinical trial of ADV110 in Australia.Acquired Suzhou Si’ao with a manufacturing center of over 18,000 square meters.

Received an approval letter from the Ethics Committee of Jiangsu Provincial Centre for Disease Control and Prevention for the commencement of a Phase II clinical trial of pGX9501.

We commenced the Phase II clinical trial of pGX9501 and successfully completed the enrolment as well as the first dosing of all planned trial subjects.Entered into a collaboration agreement with Inovio relating to joint development, manufacturing and commercialization of pGX9501 (INO4800).

The Company was converted into a joint stock company.Suzhou Advaccine was accredited as a “High- and NewTechnology Enterprise”.

Environmental Health and Safety

Advaccine strives to operate our facilities in a manner that protects the environment and the health and safety of our employees and communities.

We have implemented company-wide environmental, health and safety, or EHS policies and operating procedures relating to waste treatment, process safety management, worker health and safety requirements, accident prevention and accident reporting and emergency planning and response.

Our EHS function is responsible for monitoring and enforcing the compliance of our operations with environment, health and safety laws and regulations. This responsibility is executed through formulation and implementation of EHS policies and procedures, EHS audits and incident response planning. We have not had any significant workplace accidents in the history of our Company.

To further ensure our compliance with applicable environmental protection and health and safety laws and regulations, we

I. Have established various guidelines governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes to ensure such guidelines are strictly enforced for the disposal of laboratory materials and wastes;
II. Inspect our equipment and facilities regularly to identify and eliminate safety hazards;
III. Provide regular safety awareness training to our employees; (iv) keep health records for all employees and conduct health examinations before, during and after their time at the company; and
IV. Conduct regular fire safety inspections, maintenance of fire-fighting equipment and regular emergency drills.

In particular, we have established and implemented guidelines in accordance with relevant PRC laws and regulations on the storage, management, handling and use of viruses and bacteria. These guidelines include those related to the recording and inspection of batches of viruses and bacteria, a multi-department approval process to obtain viruses and bacteria from our inventory, as well as the safe disposal of viruses and bacteria. Our employees with specified responsibilities, including handling certain equipment and conducting animal research, are required to hold relevant qualifications, as well as wearing proper safety gear when working. We conduct safety inspections of our manufacturing facility regularly.